Next Article in Journal
DNN-m6A: A Cross-Species Method for Identifying RNA N6-methyladenosine Sites Based on Deep Neural Network with Multi-Information Fusion
Previous Article in Journal
Temporal Dynamic Methods for Bulk RNA-Seq Time Series Data
Previous Article in Special Issue
Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 12
Issue 3
10.3390/genes12030353
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome

by
Vittoria Disciglio
1,*,†,
Giovanna Forte
1,†,
Candida Fasano
1,
Paola Sanese
1,
Martina Lepore Signorile
1,
Katia De Marco
1,
Valentina Grossi
1,
Filomena Cariola
1 and
Cristiano Simone
1,2,*
1
Medical Genetics, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, 70013 Bari, Italy
2
Department of Biomedical Sciences and Human Oncology (DIMO), Medical Genetics, University of Bari Aldo Moro, 70124 Bari, Italy
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to the work.
Genes 2021, 12(3), 353; https://0-doi-org.brum.beds.ac.uk/10.3390/genes12030353
Submission received: 31 December 2020 / Revised: 22 February 2021 / Accepted: 22 February 2021 / Published: 28 February 2021
(This article belongs to the Special Issue Colorectal Cancer Genetics, Epigenetics, and Emerging Therapies)
Browse Figures
Versions Notes

Abstract

:
Familial adenomatous polyposis (FAP) is caused by germline mutations in the tumor suppressor gene APC. To date, nearly 2000 APC mutations have been described in FAP, most of which are predicted to result in truncated protein products. Mutations leading to aberrant APC splicing have rarely been reported. Here, we characterized a novel germline heterozygous splice donor site mutation in APC exon 12 (NM_000038.5: c.1621_1626+7del) leading to exon 12 skipping in an Italian family with the attenuated FAP (AFAP) phenotype. Moreover, we performed a literature meta-analysis of APC splicing mutations. We found that 119 unique APC splicing mutations, including the one described here, have been reported in FAP patients, 69 of which have been characterized at the mRNA level. Among these, only a small proportion (9/69) results in an in-frame protein, with four mutations causing skipping of exon 12 or 13 with loss of armadillo repeat 2 (ARM2) and 3 (ARM3), and five mutations leading to skipping of exon 5, 7, 8, or (partially) 9 with loss of regions not encompassing known functional domains. The APC splicing mutations causing skipping of exon 12 or 13 considered in this study cluster with the AFAP phenotype and reveal a potential molecular mechanism of pathogenesis in FAP disease.

1. Introduction

Familial adenomatous polyposis (FAP; OMIM # 175100) is an autosomal dominant disorder characterized by the development of hundreds to thousands of colorectal adenomatous polyps, which, if left untreated, progress to colorectal cancer (CRC) [1,2,3]. FAP patients may develop various extracolonic manifestations, including desmoid tumors, gastrointestinal polyposis, hepatoblastoma, thyroid cancer, and other malignancies [4,5,6,7,8]. Based on the number of colorectal polyps, onset age, and extracolonic manifestations, FAP can be classified into four forms: (1) classic FAP with profuse polyposis (>1000 adenomas); (2) classic FAP with intermediate colonic polyposis (100–1000 adenomas); (3) attenuated FAP (AFAP, <100 adenomas); (4) gastric polyposis and desmoid FAP (GD-FAP), which is characterized by less than 50 polyps, a higher risk of developing desmoid tumors, and a greater susceptibility to give rise to profuse gastric polyposis or adenomas [4,9].
FAP is caused by germline mutations in the tumor suppressor gene APC, which is located on chromosome 5 and comprises 15 translated exons. Depending on the tissues in which it is expressed, APC undergoes alternative splicing leading to multiple protein variants whose molecular weight varies from 90 to 300 kDa [10,11,12,13,14,15,16,17]. The most abundant APC transcript encodes a 2843 amino acid protein [18].
To date, nearly 2000 APC mutations have been described in FAP. The vast majority of these mutations are predicted to result in truncated protein products due to nonsense or frameshift variants or large genomic deletions [19]. Mutations predicted to result in APC aberrant splicing have rarely been reported. Isoforms lacking exon 9 or exon 14 owing to splice site mutations have also been associated with FAP disease [20,21,22,23].
In this study, we identified and molecularly characterized a novel germline heterozygous splice donor site mutation in APC exon 12 (NM_000038.5: c.1621_1626+7del) segregating with the AFAP phenotype in an Italian family. Moreover, we expanded our investigation by performing a meta-analysis to correlate all molecularly characterized APC exon 12 and exon 13 splicing mutations with FAP clinical phenotypes.

2. Materials and Methods

2.1. Patient Recruitment

The index patient underwent genetic testing following informed consent. Molecular testing carried out in this study is based on the routine clinical diagnostic assessment performed at our Institute. Written informed consent to perform genetic testing and further studies was obtained from the patient using a form approved by the competent ethics committee, in line with the principles of the Declaration of Helsinki and any other applicable local ethical and legal requirements (protocol code N° 170-date of approval 31 October 2016).

2.2. Mutation Analysis

Genomic DNA was extracted from peripheral blood with the QIAamp DNA Blood Mini Kit (Qiagen, Carlsbad, CA, USA) according to the manufacturer’s instructions. APC complete coding region was screened for mutations as previously described [24] using primer sequences previously published by Groden J et al. [12]. In order to scan the exons for mutations, the APC gene was divided into 23 amplicons using specific primer pairs, with seven amplicons covering exon 15. Each amplicon was sequenced in forward and reverse directions with the same primers used for PCR amplification or internal sequencing primers (Table S1). PCR sequencing and capillary electrophoresis were performed on an Applied Biosystems 3130 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA). Mutations and polymorphisms were confirmed in independently amplified PCR products. The global population frequency of the identified APC variant was retrieved from the 1000 Genome [25,26], dbSNP [27,28], gnomAD [29,30], and NHLBI Exome Sequencing Project (ESP) [31,32] databases. Moreover, the HGMD Professional [33], InSiGHT [34,35], and Clinvar [36,37] databases were interrogated to assess the pathogenicity of the identified variant.
To evaluate the effect of the APC c.1621_1626+7del mutation on RNA splicing, four splice site prediction algorithms integrated into Alamut Visual version 2.15 (Sophia Genetics SAS; Bidart, France) were interrogated simultaneously: Splice Site Finder (SSF), MaxEntScan (MES), Splice Site Prediction by Neural Network (NNS), and Gene Splicer (GS). The default thresholds of each tool were used for the analysis. A variation of more than 10% in at least two algorithms was considered as having an effect on the splicing process.
The identified variant was classified according to the American College of Medical Genetics and Genomics (ACMG) and the Association of Molecular Pathology (AMP) variant classification scheme [38].

2.3. RT-PCR and mRNA Analysis

Total RNA from peripheral blood was extracted with the QIAamp RNA Blood Mini Kit (Qiagen) according to the manufacturer’s instructions. One microgram of RNA was reverse-transcribed to cDNA using the Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The 5′ and 3′ flanking regions of the APC mutation site (NM_000038.5: c.1621_1626+7del) were amplified using the Phusion Hot Start II DNA Polymerase (Thermo Fisher Scientific) and the following primers (10 pmol each): APC_Ex10-11_Fw (NM_000038.5) GAATGAACTAGGGGGACTACAGGC, and APC_Ex13-14_Rv (NM_000038.5) GGGTTGATTCCTTTTTAACTTC. PCR amplification was carried out at 98 °C for 30 s, followed by 35 cycles at 98 °C for 10 s, 60 °C for 10 s, and 72 °C for 15 s, with a final elongation at 72 °C for 5 min. PCR products were loaded onto 3% agarose gel in 0.5X TBE and visualized using SYBR Safe DNA Gel Stain (Thermo Fisher Scientific). Sequencing and capillary electrophoresis were performed on an Applied Biosystems 3130 Genetic Analyzer.

2.4. Cell Line

The HEK-293 cell line was purchased from ATCC and cultured in DMEM high glucose (HG), without pyruvate (Thermo Fisher Scientific) with 10% FBS (Thermo Fisher Scientific), 1% pyruvate (Thermo Fisher Scientific), 1% NEAA (Thermo Fisher Scientific), and 100 U/ml penicillin–streptomycin (Thermo Fisher Scientific) in a 37 °C and 5% CO2 incubator. The cell line was tested to be mycoplasma-free according to Venor®GeM Advance kit (Minerva Biolabs, Berlin, Germany) at multiple times throughout the study.

2.5. Plasmid Construct and Expression

Fragments with the wild type or mutant alleles containing APC exon 12 (NM_000038.5), flanked by upstream (311 nt) and downstream (447 nt) intronic sequences, were amplified using the following primers: Cloning_APC_Fw_EcoRI ACCAGTGAATTCGACCAAGGCAAGTGTTACACAC, and Cloning_APC_Rv_BamHI ACCGATGGATCCTCCTAAATGCTACTACAGTGCC. Fragments were cloned into the splicing vector pSPL3, linearized with EcoRI and BamHI. All constructs were confirmed by direct sequencing.

2.6. In Vitro Splicing Assay

HEK-293 cells were transfected using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s instruction for 24 h. Cells were harvested, total RNA was extracted with the PureLink™ RNA Mini Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions, and used for RT-PCR to confirm splicing patterns. cDNA was synthesized as described above and used as a template for PCR amplification with the following vector-specific primers: SD6_ FW GTCTGAGTCACCTGGACAACC and SA2_ RV GATCTCAGTGGTATTTGTGAGC. PCR amplification was carried out with the Phusion High-Fidelity DNA Polymerase at 98 °C for 30 s, followed by 35 cycles at 98 °C for 10 s, 52 °C for 10 s, and 72 °C for 15 s, with a final elongation at 72 °C for 5 min. PCR products were loaded onto 2% agarose gel in 0.5X TBE and visualized using SYBR Safe DNA Gel Stain. Sequencing and capillary electrophoresis were performed on an Applied Biosystems 3130 Genetic Analyzer.

2.7. Meta-Analysis

The meta-analysis of APC splicing mutations was performed on the Human Gene Mutation Database Professional (HGMD Professional; Qiagen), a comprehensive collection of germline mutations in nuclear genes that are associated with human-inherited diseases [33]. We reviewed all the papers identified in the aforementioned database and collected relevant clinical information (i.e., gender, age at diagnosis, gastric or colonic polyposis, and specific APC mutations). Studies including patients without clinical information were excluded.

3. Results

3.1. Clinical History and Genetic Findings

The index case was a 53-year-old male referred to our institution for genetic counseling. The patient presented at 41 years of age with an attenuated colorectal phenotype (AFAP phenotype), which is consistent with the presence of two intestinal polyps. Histological examination revealed tubular adenomas measuring 4 and 6 mm with moderate-grade dysplasia. After one year, colonoscopy examination did not show evidence of polyposis. The patient was followed up with yearly colonoscopy, which showed three tubular adenomas (2.5 mm) with moderate-grade dysplasia in the large bowel at the age of 43 and two adenomatous polyps (2 mm) with high-grade dysplasia in the sigmoid colon at the age of 44. The patient developed small polyps at the age of 48 and numerous sessile polyps throughout the colon at the age of 51. After one year, colonoscopy examination revealed the presence of various polypoid and non-polypoid lesions in the transverse and descending colon. The patient had a positive family history of colorectal cancer and colon polyposis (Figure 1).
The brother of the proband exhibited signs of attenuated FAP, showing diffuse polyposis of the colon (<100), and underwent subtotal colectomy at 48 years of age. The mother of the proband developed colorectal carcinomas at the age of 65 and 77. Moreover, she developed an adenomatous polyp at the age of 80. Evaluation of the family history revealed that a maternal aunt of the proband underwent total colectomy for multiple colon polyps (<100). Furthermore, two maternal aunts developed adenomatous polyps of the colon and were diagnosed with colorectal cancer at the age of 60 and 65, respectively (Figure 1). The APC mutation analysis performed on the proband’s DNA revealed a heterozygous splicing mutation in APC exon 12 (NM_000038.5: c.1621_1626+7del) (Figure 2A).
The identified variant was found to be rare since it was not listed in global population databases (1000 Genome, dbSNP, gnomAD, NHLBI ESP). Moreover, this variant has never been reported in major disease-associated databases (HGMD Professional, InSiGHT, and Clinvar). In silico analysis using four algorithms (SSF, MES, NNS, and GS) integrated into Alamut Visual version 2.15 (Sophia Genetics SAS) revealed that APC c.1621_1626+7del mutation may result in a splice defect due to loss of the canonical donor site at position c.1626 of the APC gene (Figure S1).

3.2. Analysis of Patient’s Processed Transcripts

To determine the effect of nucleotide deletion c.1621_1626+7del, total RNA was isolated from peripheral blood of the proband and an unrelated control. The APC transcript between exons 10 and 14 was amplified by RT-PCR, and the obtained fragments were isolated and sequenced (Figure 2B). Gel electrophoresis of the PCR products showed an expected-size fragment (356 bp) both in control and patient samples; however, a lower fragment (277 bp) was also found in the latter. Sequencing analysis of this fragment showed that the c.1621_1626+7del mutation results in the loss of exon 12 splice donor site and exon 12 skipping (Figure 2B). To confirm our results, we performed a minigene study using the pSPL3 plasmid. As described in the Section 2, fragments with the wild type or mutant exon 12 (78 bp) allele, flanked by upstream (311 nt) and downstream (447 nt) intronic sequences, were cloned into the splicing vector pSPL3 (Figure 3A). The pSPL3 empty vector, pSPL3_APC_wt, and pSPL3_APC_ Δ1621_1626+7 were transfected into HEK-293 cells for 24 hours, and the RNA was collected. Minigene assays showed that the wild type construct resulted in a 341 bp PCR product containing exon 12, while both the empty vector and the mutant construct produced a 263 bp PCR product missing APC exon 12. The obtained fragments were confirmed by sequencing analysis (Figure 3B).

3.3. Meta-Analysis

We performed a literature meta-analysis of APC splicing mutations to identify disease-causing splice site mutations that do not change the reading frame of the aberrant transcript and to evaluate their effect on transcript processing and patient phenotype. So far, 119 unique APC splicing mutations, including the one characterized in the present study, have been reported in FAP patients. Of these, 69 (58%) have been molecularly characterized at the mRNA level and mainly (60/69, 87%) cause a reading frame shift, while a very small proportion (9/69, 13%) leads to an in-frame APC protein [39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88] (Table S2). Specifically, among the splicing mutations leading to an in-frame protein, 4/9 cause exon 12 or exon 13 skipping with loss of armadillo repeat 2 (ARM2) and armadillo repeat 3 (ARM3) in the APC N-terminal armadillo repeat domain. Of these, 3 were reported in patients with AFAP phenothype [45,54,59] (Table 1). The remaining molecularly characterized splicing mutations leading to an in-frame protein (5/9) result in skipping of exon 5, 7, 8, or (partially) 9 with loss of APC regions not encompassing known functional sites/domains [45,54,67] (Table S3).
In order to provide further insight into the relationship between APC exon 12 or exon 13 splicing mutations leading to an in-frame protein, the clinical phenotype, and the potential underlying molecular mechanisms in FAP disease, we retrieved clinical and molecular data of FAP patients bearing truncating mutations that lead to partial or total removal of ARM2 and/or ARM3 and disrupt all downstream APC protein domains [50,53,71,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105] (Table S4). Then, we sought to compare the phenotypic consequences of splicing mutations leading to in-frame amino acid deletions within the ARM2 or ARM3 motifs of the APC protein N-terminal armadillo repeat domain with those of truncating mutations located in the ARM2 (aa 505–547) or ARM3 (aa 548–591) domains leading to partial or total removal of ARM2 and/or ARM3 and disrupting all APC downstream regions (aa 505–2843), including the β-catenin-regulating domains (Figure 4).
A total of 33 patients with data on colon polyposis clinical phenotype and truncating alterations located in the ARM2 and ARM3 domains of APC were identified: (i) 12 patients harbored a truncating mutation involving the ARM2 domain, (ii) four patients harbored a truncating mutation involving the ARM2 and ARM3 domains, and (iii) 17 patients harbored a truncating mutation in the ARM3 domain. In this cohort, the percentage of patients with the classic FAP clinical phenotype was higher (29/33, 87.9%) than the percentage of patients with the attenuated FAP clinical phenotype (4/33, 12.1%). Furthermore, the classic FAP clinical phenotype was only observed in patients with APC truncating mutations, whereas all the patients with splicing mutations leading to in-frame amino acid deletions involving APC ARM2 or ARM3 motifs exhibited the attenuated clinical variant of the disease.

4. Discussion

RNA splicing is a key cellular process that governs several biological processes, including cellular proliferation, survival, and differentiation [106]. Dysregulation of pre-mRNA splicing is increasingly recognized as an important mechanism that is linked to cancer [107]. In the context of multistep carcinogenesis of CRC, genetic lesions that affect APC splicing are likely to significantly contribute to the etiology of the disease.
APC is a crucial tumor suppressor gene in both sporadic and hereditary CRC. It encodes a large multifunctional protein comprising several motifs and domains, including an oligomerization domain, an ARM domain, a region containing several β-catenin-binding repeats and axin-binding repeats, and a basic domain that interacts with the microtubules. The wild type APC protein plays an important role in Wnt signaling by promoting the degradation of β-catenin. Due to its interaction with a variety of other proteins, APC is also involved in cellular processes related to cell migration, cell adhesion, proliferation, differentiation, and chromosome segregation [108].
APC mutational inactivation is a key event in the development of colon cancer and the intestinal polyp disorder FAP. The severity of the FAP phenotype depends on the location of APC mutations, indicating a complex role for APC that extends beyond the canonical Wnt pathway [9,108].
Most APC disease-causing variants result in a premature termination codon impairing protein function; however, a minor fraction has been found to disrupt the splicing pattern of the gene [4]. In light of the above, the functional characterization and clinical classification of aberrant splicing variants involving the APC gene may support diagnostic accuracy in medical genetics. In this study, we report a novel splicing mutation in the APC tumor suppressor gene. This variant was identified by direct sequencing in an Italian AFAP family and consists of a small deletion involving the last six nucleotides of exon 12 and seven nucleotides including the splice donor site of intron 12 (c.1621_1626+7del).
The frequency of this mutation was assessed by interrogating various population databases. This analysis revealed that APC c.1621-1626+7del variant is not listed in the dbSNP, 1000 Genome, gnomAD, and ESP databases. To assess the putative effect of this variant on the splicing process, we performed an in silico analysis using splicing prediction tools, which indicated a potential splicing alteration due to the loss of APC exon 12 canonical splice donor site.
To confirm whether this mutation could affect APC splicing, RNA was isolated from the proband, the APC transcript between exon 10 and 14 was amplified by RT-PCR, and the obtained products were isolated and sequenced, revealing the absence of APC exon 12. Moreover, to ascertain the in vivo relevance of the effect of the identified APC mutation on splicing, we performed a minigene splicing assay. Our results showed that APC c.1621-1626+7del variant affects the splicing process, resulting in complete skipping of exon 12. However, this deletion does not disrupt the open reading frame of the aberrant transcript, which lacks some, but not all, Armadillo repeat motifs.
According to ACMG/AMP criteria, our clinical and molecular characterization of the identified variant provides evidence of pathogenicity.
Next, we performed a meta-analysis to investigate the correlation between APC exon 12 or exon 13 splicing mutations that lead to an in-frame protein lacking functional domains/sites and the corresponding clinical phenotypes. To date, nearly 2000 APC mutations have been described in FAP, almost all of which (~87%) lead to loss of function (nonsense mutations, small deletions, small insertions, and gross rearrangements), while only a few (~6 %) have been reported to cause or potentially cause impaired splicing of the gene product. The remaining APC mutations are missense mutations and mutations in regulatory regions of the gene (data obtained from HGMD Professional) [33]. Our literature analysis revealed that only a small proportion of these splice site mutations (69/119) have been characterized at the mRNA level, with the vast majority (60/69, 87%) causing a reading frame shift and a tiny fraction (9/69, 13%) leading to an in-frame APC protein with loss of functional domains/sites (Table S2).
Specifically, among the molecularly characterized splicing mutations leading to an in-frame protein, 5/9 cause skipping of exon 5, 7, 8, or (partially) 9 with loss of APC regions not encompassing known functional sites/domains, while 4/9 have been reported to cause the deletion of exon 12 (p.Ala517_Gly542del) or 13 (p.Val543_Lys581) with loss of ARM2 and/or ARM3.
Splicing mutations causing the loss of armadillo functional domains have been reported in patients with FAP disease.
Interestingly, deletion of exon 13 (p.Val543_Lys581del) leads to the loss of the last five amino acids of ARM2 and an almost complete loss of ARM3.
Skipping of exon 13 has been reported to be associated with a mutation in a highly conserved splice acceptor site (c.1627G>T, the first base of exon 13) in a patient with AFAP phenotype who underwent subtotal colectomy for carcinoma at the age of 60 [54]. In another report, skipping of exon 13 was found to be caused by a missense mutation in exon 13 (c.1742A>G) that was detected in a patient with attenuated FAP [59]. Splicing mutations resulting in the loss of exon 12 (p.Ala517_Gly542del) lead to an almost complete loss of ARM2. Skipping of exon 12 has been reported to be associated with a mutation in a highly conserved splice donor site (c.1626G>C, the last base of exon 12) in a patient with FAP disease whose clinical phenotype was not described [45].
Based on clinical evaluation (age of manifestation, number and size of polyps, and absence of colorectal cancer until the age of 35), the patient carrying the newly identified APC splicing mutation c.1621_1627+7del described in this study and its family were classified as having an attenuated form of FAP.
Patients with AFAP tend to develop fewer adenomatous polyps, with colorectal tumors occurring at an older age compared with patients with classic FAP. Genotype–phenotype association studies have revealed that AFAP patients mainly carry mutations at the 5’ end of the gene or at splice junctions involving the alternatively spliced region of exon 9 [4].
Specifically, mutations located in exon 9 alternative splice site have been reported to cause inefficient exon skipping resulting in the generation of a shorter APC isoform along with normal transcripts from the mutant allele [39,43,45,47,54,72]. A recent study investigating the molecular mechanisms leading to AFAP in patients carrying a mutation in the alternatively spliced region of exon 9 has suggested that a “third hit” (somatic mutations of both APC alleles) is necessary for tumorigenesis to occur in these patients [109].
In an effort to elucidate the correlation between mutations causing in-frame loss of functional ARM repeat domains and clinical phenotypes, we compared the clinical and molecular data of FAP patients carrying APC splicing mutations that lead to an in-frame protein lacking ARM2 and/or ARM3 with those bearing APC truncating mutations that result in partial or total removal of ARM2 and/or ARM3 along with disruption of all downstream domains.
Our results demonstrated a trend towards the development of a milder FAP phenotype (attenuated FAP) in patients with splicing mutations in ARM2 and/or ARM3 compared to patients with truncating mutations. The attenuated phenotype observed in patients harboring APC mutations that lead to loss of exon 12 or 13 and cause partial deletion of ARM motifs suggests a potential mechanism of pathogenesis in FAP disease.
ARM domains are abundant in eukaryotic proteins and are characterized by tandem armadillo repeats of approximately 42 amino acids in length that participate in protein-protein interaction. ARM domains are involved in a broad range of important cellular processes, including signal transduction, nuclear transport, and regulation of cytoskeleton formation [110].
The ARM domain located at APC N-terminal is encoded by exons 10–14 and contains seven armadillo repeats that provide a structural platform for interaction with several other proteins, including SAM68 [111], ASEF [112], KAP3 [113], IQGAP1 [114], and AMER1 [115]. The structural diversity of these binding partners reveals that APC armadillo repeats may be involved in Wnt signaling, cell–cell adhesion, cell polarization, and cell migration. It has also been reported that the loss of ARM domains results in increased tumor initiation, suggesting a putative tumor-suppressive function for this region [116,117]. Furthermore, previous studies on co-crystal structures showed that the replacement of APC key residues, such as N507K, N550K, N594K, and K516/E, abolishes the association between APC-ARM and AMER1-A1/A2/A4 [115], ASEF [118], and SAM68 [111]. These APC ligands show no apparent sequence similarity, nor do they have any resemblance with other APC-binding motifs. However, in their physical interaction with APC, these proteins occupy the same surface groove within APC-ARM domains and assume the same antiparallel position with respect to armadillo repeats [115].
The evidence that addition of the ASEF protein to preassembled APC-ARM/A MER1 complexes progressively dissociates APC-ARM from AMER1 in a dose-dependent manner confirms the hypothesis that these APC partners can compete with each other in a mutually exclusive manner [115].
Consistently, from a functional point of view, AMER1 and SAM68 seem to have antithetical roles in the regulation of the Wnt pathway. In particular, AMER1 negatively regulates Wnt signal transduction by promoting ubiquitination and degradation of β-catenin [119], while recent data showed that aberrant upregulation of SAM68 induces cancer cell proliferation in vitro by activating the Wnt/β-catenin signaling pathway [120]. Note that it has also been reported that the complex between APC and SAM68 regulates the alternative splicing of members of the T cell factor (TCF) family of transcription factors that associate with β-catenin, in the presence of the Wnt signal or in the absence of APC, in order to regulate the expression of Wnt target genes involved in tumor formation. APC mutations that truncate regions downstream of the ARM domain lead to the accumulation of the TCF-1E splice variant, which strongly transactivates Wnt target genes [111].
Note also that genetic disease mutations can have an impact on protein conformational equilibria and dynamics [121,122]. Recently, the missense APC N1026S variant identified in an AFAP family has been predicted to change the conformational flexibility of APC protein, preventing it from establishing stable contacts with β-catenin protein [123].
In this light, another possible explanation as to why mutations causing partial deletion of APC ARM1 and/or ARM2 motifs could produce an attenuated phenotype is that these deletions may induce conformational changes in protein structure and dynamics resulting in impaired physical interaction between APC and its binding partners, including β-catenin. It is therefore tempting to speculate that APC exon 12 or exon 13 splicing mutations leading to the deletion of ARM motifs may decrease APC binding to β-catenin, thereby preventing, at least in part, the export of nuclear β-catenin. This would in turn result in an attenuated clinical variant of FAP disease.Conversely, truncating mutations located in the ARM2 and/or ARM3 motifs lead to complete lack of regulation of the β-catenin protein, causing the classic clinical variant of FAP disease.
For these reasons, APC exon 12 or exon 13 splicing mutations leading to the partial loss of ARM motifs are expected to account for the observed AFAP phenotype in the patients considered in the present study.

5. Conclusions

Altogether, the presented evidence supports mechanism for FAP pathogenesis involving mutations that affect APC ARM domains but do not cause the loss of the seven β-catenin-downregulating 20 amino acid repeats distributed in the central region of the protein. The underlying mechanism of pathogenesis most likely involves binding partners and functions of APC ARM motifs, suggesting that these domains mediate APC tumor suppressor activity and may play a role in carcinogenesis in FAP patients.In conclusion, our findings support a pathogenic role for APC exon 12 or exon 13 splicing mutations in the AFAP phenotype.

Supplementary Materials

The following supplementary figure and tables are available online at https://0-www-mdpi-com.brum.beds.ac.uk/2073-4425/12/3/353/s1. Figure S1: Screenshot from the Alamut software. Splicing effect window around APC c.1621_1626+7del mutation. The top box represents APC wild-type sequence; the bottom box represents APC mutated sequence with the c.1621_1626+7del deletion. The dark blue bars represent the predicted splice donor site. The diagram reveals the abolition of the canonical splice donor site at position c.1626. All four tools predicted that the identified variant abolishes the canonical splice donor site. Table S1: Primers used for genomic PCR amplification and sequencing reactions; Table S2: APC splicing mutations; Table S3: APC splicing mutations leading to an in-frame protein and loss of APC regions not encompassing known functional sites/domains; Table S4: Truncating mutations located in the ARM2 or ARM3 domain of the APC protein.

Author Contributions

Conceptualization, V.D. and C.S.; methodology, V.D., G.F. and F.C.; validation, V.D. and G.F.; formal analysis, V.D., G.F. and C.F.; investigation, V.D. and G.F.; resources, V.D. G.F., C.S., P.S.; M.L.S., K.D.M. and V.G.; data curation, V.D., G.F., C.S., P.S.; M.L.S., K.D.M. and V.G.; writing—original draft preparation, V.D., G.F. and C.F.; writing—review and editing, V.D. and C.S.; visualization, V.D.; supervision, C.S.; project administration, C.S.; funding acquisition, C.S. All authors have read and agreed to the published version of the manuscript.

Funding

The research leading to these results has received funding from AIRC under IG 2019—ID. 23794 project—P.I. C.S. Furthermore, this work was funded by the research funding program “Ricerca Corrente 2018–2020; 2019–2021” to C.S. and “Starting Grant” SG-2019-12371540 to P.S from the Italian Ministry of Health and by the 2017 PRIN (Research Projects of National Relevance) n. 2017WNKSLr-LS4 from the Italian MIUR to C.S.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee of IRCCS Istituto Tumori “Giovanni Paolo II” (protocol code N° 170, date of approval 31 October 2016).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Acknowledgments

We thank Francesco Paolo Jori for his helpful discussion during the preparation of the manuscript and editorial assistance. We acknowledge Alessandro Stella at Medical Genetics (Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari “Aldo Moro”, Bari, Italy) for providing the splicing vector pSPL3. We acknowledge Andrea Manghisi and Filomena Anna Guglielmi for technical support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Markowitz, S.D.; Bertagnolli, M.M. Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer. N. Engl. J. Med. 2009, 361, 2449–2460. [Google Scholar] [CrossRef] [Green Version]
  2. Kanth, P.; Grimmett, J.; Champine, M.; Burt, R.; Samadder, N.J. Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management. Am. J. Gastroenterol. 2017, 112, 1509–1525. [Google Scholar] [CrossRef]
  3. Church, J. Molecular Genetics of Colorectal Cancer. Semin. Colon Rectal Surg. 2016, 27, 172–175. [Google Scholar] [CrossRef]
  4. Nieuwenhuis, M.H.; Vasen, H.F.A. Correlations between Mutation Site in APC and Phenotype of Familial Adenomatous Polyposis (FAP): A Review of the Literature. Crit. Rev. Oncol. Hematol. 2007, 61, 153–161. [Google Scholar] [CrossRef] [PubMed]
  5. Caspari, R.; Olschwang, S.; Friedl, W.; Mandl, M.; Boisson, C.; Böker, T.; Augustin, A.; Kadmon, M.; Möslein, G.; Thomas, G. Familial Adenomatous Polyposis: Desmoid Tumours and Lack of Ophthalmic Lesions (CHRPE) Associated with APC Mutations beyond Codon 1444. Hum. Mol. Genet. 1995, 4, 337–340. [Google Scholar] [CrossRef] [PubMed]
  6. Friedl, W.; Caspari, R.; Sengteller, M.; Uhlhaas, S.; Lamberti, C.; Jungck, M.; Kadmon, M.; Wolf, M.; Fahnenstich, J.; Gebert, J.; et al. Can APC Mutation Analysis Contribute to Therapeutic Decisions in Familial Adenomatous Polyposis? Experience from 680 FAP Families. Gut 2001, 48, 515–521. [Google Scholar] [CrossRef] [Green Version]
  7. Enomoto, M.; Konishi, M.; Iwama, T.; Utsunomiya, J.; Sugihara, K.I.; Miyaki, M. The Relationship between Frequencies of Extracolonic Manifestations and the Position of APC Germline Mutation in Patients with Familial Adenomatous Polyposis. JPN J. Clin. Oncol. 2000, 30, 82–88. [Google Scholar] [CrossRef] [Green Version]
  8. Bertario, L.; Russo, A.; Sala, P.; Varesco, L.; Giarola, M.; Mondini, P.; Pierotti, M.; Spinelli, P.; Radice, P.; Hereditary Colorectal Tumor Registry. Multiple Approach to the Exploration of Genotype-Phenotype Correlations in Familial Adenomatous Polyposis. J. Clin. Oncol. 2003, 21, 1698–1707. [Google Scholar] [CrossRef] [PubMed]
  9. Disciglio, V.; Fasano, C.; Cariola, F.; Forte, G.; Grossi, V.; Sanese, P.; Lepore Signorile, M.; Resta, N.; Lotesoriere, C.; Stella, A.; et al. Gastric Polyposis and Desmoid Tumours as a New Familial Adenomatous Polyposis Clinical Variant Associated with APC Mutation at the Extreme 3’-End. J. Med. Genet. 2020, 57, 356–360. [Google Scholar] [CrossRef] [Green Version]
  10. Horii, A.; Nakatsuru, S.; Ichii, S.; Nagase, H.; Nakamura, Y. Multiple Forms of the APC Gene Transcripts and Their Tissue-Specific Expression. Hum. Mol. Genet. 1993, 2, 283–287. [Google Scholar] [CrossRef] [PubMed]
  11. Thliveris, A.; Samowitz, W.; Matsunami, N.; Groden, J.; White, R. Demonstration of Promoter Activity and Alternative Splicing in the Region 5’ to Exon 1 of the APC Gene. Cancer Res. 1994, 54, 2991–2995. [Google Scholar]
  12. Groden, J.; Thliveris, A.; Samowitz, W.; Carlson, M.; Gelbert, L.; Albertsen, H.; Joslyn, G.; Stevens, J.; Spirio, L.; Robertson, M. Identification and Characterization of the Familial Adenomatous Polyposis Coli Gene. Cell 1991, 66, 589–600. [Google Scholar] [CrossRef]
  13. Oshima, M.; Sugiyama, H.; Kitagawa, K.; Taketo, M. APC Gene Messenger RNA: Novel Isoforms That Lack Exon 7. Cancer Res. 1993, 53, 5589–5591. [Google Scholar]
  14. Samowitz, W.S.; Thliveris, A.; Spirio, L.N.; White, R. Alternatively Spliced Adenomatous Polyposis Coli (APC) Gene Transcripts That Delete Exons Mutated in Attenuated APC. Cancer Res. 1995, 55, 3732–3734. [Google Scholar] [PubMed]
  15. Suleková, Z.; Ballhausen, W.G. A Novel Coding Exon of the Human Adenomatous Polyposis Coli Gene. Hum. Genet. 1995, 96, 469–471. [Google Scholar] [CrossRef] [PubMed]
  16. Sulekova, Z.; Reina-Sanchez, J.; Ballhausen, W.G. Multiple APC Messenger RNA Isoforms Encoding Exon 15 Short Open Reading Frames Are Expressed in the Context of a Novel Exon 10A-Derived Sequence. Int. J. Cancer 1995, 63, 435–441. [Google Scholar] [CrossRef]
  17. Xia, L.; St Denis, K.A.; Bapat, B. Evidence for a Novel Exon in the Coding Region of the Adenomatous Polyposis Coli (APC) Gene. Genomics 1995, 28, 589–591. [Google Scholar] [CrossRef] [PubMed]
  18. Sieber, O.M.; Tomlinson, I.P.; Lamlum, H. The Adenomatous Polyposis Coli (APC) Tumour Suppressor—Genetics, Function and Disease. Mol. Med. Today 2000, 6, 462–469. [Google Scholar] [CrossRef]
  19. Leoz, M.L.; Carballal, S.; Moreira, L.; Ocaña, T.; Balaguer, F. The Genetic Basis of Familial Adenomatous Polyposis and Its Implications for Clinical Practice and Risk Management. Appl. Clin. Genet. 2015, 8, 95–107. [Google Scholar] [PubMed] [Green Version]
  20. Cama, A.; Esposito, D.L.; Palmirotta, R.; Curia, M.C.; Ranieri, A.; Ficari, F.; Valanzano, R.; Modesti, A.; Battista, P.; Tonelli, F. A Novel Mutation at the Splice Junction of Exon 9 of the APC Gene in Familial Adenomatous Polyposis. Hum. Mutat. 1994, 3, 305–308. [Google Scholar] [CrossRef]
  21. Varesco, L.; Gismondi, V.; Presciuttini, S.; Groden, J.; Spirio, L.; Sala, P.; Rossetti, C.; De Benedetti, L.; Bafico, A.; Heouaine, A. Mutation in a Splice-Donor Site of the APC Gene in a Family with Polyposis and Late Age of Colonic Cancer Death. Hum. Genet. 1994, 93, 281–286. [Google Scholar] [CrossRef] [PubMed]
  22. Bala, S.; Sulekova, Z.; Ballhausen, W.G. Constitutive APC Exon 14 Skipping in Early-Onset Familial Adenomatous Polyposis Reveals a Dramatic Quantitative Distortion of APC Gene-Specific Isoforms. Hum. Mutat. 1997, 10, 201–206. [Google Scholar] [CrossRef]
  23. Hamzehloei, T.; West, S.P.; Chapman, P.; Burn, J.; Curtis, A. Mutation Detection in Exons 1-14 of the Adenomatous Polyposis Coli Gene: Identification of an Alternatively Spliced Transcript. Mol. Cell Probes 1996, 10, 379–385. [Google Scholar] [CrossRef]
  24. Resta, N.; Stella, A.; Susca, F.; Montera, M.; Gentile, M.; Cariola, F.; Prete, F.; Tenconi, R.; Tibiletti, M.G.; Logrieco, G.; et al. Nine Novel APC Mutations in Italian FAP Patients. Hum. Mutat. 2001, 17, 434–435. [Google Scholar] [CrossRef]
  25. Genome Browsers 1000 Genomes. Available online: http://www.internationalgenome.org/1000-genomes-browsers/ (accessed on 18 December 2020).
  26. 1000 Genomes Project Consortium; Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A.; et al. A Global Reference for Human Genetic Variation. Nature 2015, 526, 68–74. [Google Scholar]
  27. dbSNP Home Page. Available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/snp/ (accessed on 18 December 2020).
  28. Smigielski, E.M.; Sirotkin, K.; Ward, M.; Sherry, S.T. dbSNP: A database of single nucleotide polymorphisms. Nucleic Acids Res. 2000, 28, 352–355. [Google Scholar] [CrossRef] [Green Version]
  29. gnomAD Browser Home Page. Available online: https://gnomad.broadinstitute.org/ (accessed on 18 December 2020).
  30. Karczewski, K.J.; Francioli, L.C.; Tiao, G.; Cummings, B.B.; Alföldi, J.; Wang, Q.; Collins, R.L.; Laricchia, K.M.; Ganna, A.; Birnbaum, D.P.; et al. The Mutational Constraint Spectrum Quantified from Variation in 141,456 Humans. Nature 2020, 581, 434–443. [Google Scholar] [CrossRef] [PubMed]
  31. NHLBI Exome Sequencing Project (ESP) Home Page. Available online: https://evs.gs.washington.edu/EVS/ (accessed on 18 December 2020).
  32. Auer, P.L.; Reiner, A.P.; Wang, G.; Kang, H.M.; Abecasis, G.R.; Altshuler, D.; Bamshad, M.J.; Nickerson, D.A.; Tracy, R.P.; Rich, S.S.; et al. Guidelines for Large-Scale Sequence-Based Complex Trait Association Studies: Lessons Learned from the NHLBI Exome Sequencing Project. Am. J. Hum. Genet. 2016, 99, 791–801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Stenson, P.D.; Mort, M.; Ball, E.V.; Evans, K.; Hayden, M.; Heywood, S.; Hussain, M.; Phillips, A.D.; Cooper, D.N. The Human Gene Mutation Database: Towards a Comprehensive Repository of Inherited Mutation Data for Medical Research, Genetic Diagnosis and next-Generation Sequencing Studies. Hum. Genet. 2017, 136, 665–677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Insight Home Page. Available online: https://www.insight-group.org/ (accessed on 18 December 2020).
  35. Tricarico, R.; Kasela, M.; Mareni, C.; Thompson, B.A.; Drouet, A.; Staderini, L.; Gorelli, G.; Crucianelli, F.; Ingrosso, V.; Kantelinen, J.; et al. InSiGHT Variant Interpretation Committee. Assessment of the InSiGHT Interpretation Criteria for the Clinical Classification of 24 MLH1 and MSH2 Gene Variants. Hum. Mutat. 2017, 38, 64–77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Clinvar Home Page. Available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/clinvar/ (accessed on 18 December 2020).
  37. Landrum, M.J.; Lee, J.M.; Riley, G.R.; Jang, W.; Rubinstein, W.S.; Church, D.M.; Maglott, D.R. ClinVar: Public Archive of Relationships among Sequence Variation and Human Phenotype. Nucleic Acids Res. 2014, 42, D980–D985. [Google Scholar] [CrossRef] [Green Version]
  38. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef] [PubMed]
  39. Kerr, S.E.; Thomas, C.B.; Thibodeau, S.N.; Ferber, M.J.; Halling, K.C. APC Germline Mutations in Individuals Being Evaluated for Familial Adenomatous Polyposis: A Review of the Mayo Clinic Experience with 1591 Consecutive Tests. J. Mol. Diagn. 2013, 15, 31–43. [Google Scholar] [CrossRef] [PubMed]
  40. Soussi, T.; Leroy, B.; Devir, M.; Rosenberg, S. High Prevalence of Cancer-Associated TP53 Variants in the GnomAD Database: A Word of Caution Concerning the Use of Variant Filtering. Hum. Mutat. 2019, 40, 516–524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Woods, M.O.; Younghusband, H.B.; Parfrey, P.S.; Gallinger, S.; McLaughlin, J.; Dicks, E.; Stuckless, S.; Pollett, A.; Bapat, B.; Mrkonjic, M.; et al. The Genetic Basis of Colorectal Cancer in a Population-Based Incident Cohort with a High Rate of Familial Disease. Gut 2010, 59, 1369–1377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Plawski, A.; Slomski, R. APC Gene Mutations Causing Familial Adenomatous Polyposis in Polish Patients. J. Appl. Genet. 2008, 49, 407–414. [Google Scholar] [CrossRef]
  43. Olschwang, S.; Laurent-Puig, P.; Groden, J.; White, R.; Thomas, G. Germ-Line Mutations in the First 14 Exons of the Adenomatous Polyposis Coli (APC) Gene. Am. J. Hum. Genet. 1993, 52, 273–279. [Google Scholar]
  44. Jarry, J.; Brunet, J.-S.; Laframboise, R.; Drouin, R.; Latreille, J.; Richard, C.; Gekas, J.; Maranda, B.; Monczak, Y.; Wong, N.; et al. A Survey of APC Mutations in Quebec. Fam. Cancer 2011, 10, 659–665. [Google Scholar] [CrossRef]
  45. Grandval, P.; Blayau, M.; Buisine, M.-P.; Coulet, F.; Maugard, C.; Pinson, S.; Remenieras, A.; Tinat, J.; Uhrhammer, N.; Béroud, C.; et al. The UMD-APC Database, a Model of Nation-Wide Knowledge Base: Update with Data from 3,581 Variations. Hum. Mutat. 2014, 35, 532–536. [Google Scholar] [CrossRef]
  46. Tsukanov, A.S.; Pospekhova, N.I.; Shubin, V.P.; Kuzminov, A.M.; Kashnikov, V.N.; Frolov, S.A.; Shelygin, Y.A. Mutations in the APC Gene in Russian Patients with Classic Form of Familial Adenomatous Polyposis. Russ. J. Genet. 2017, 53, 369–375. [Google Scholar] [CrossRef]
  47. Aretz, S.; Uhlhaas, S.; Sun, Y.; Pagenstecher, C.; Mangold, E.; Caspari, R.; Möslein, G.; Schulmann, K.; Propping, P.; Friedl, W. Familial Adenomatous Polyposis: Aberrant Splicing Due to Missense or Silent Mutations in the APC Gene. Hum. Mutat. 2004, 24, 370–380. [Google Scholar] [CrossRef] [PubMed]
  48. Friedl, W.; Aretz, S. Familial Adenomatous Polyposis: Experience from a Study of 1164 Unrelated German Polyposis Patients. Hered. Cancer Clin. Pract. 2005, 3, 95–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. González, S.; Blanco, I.; Campos, O.; Julià, M.; Reyes, J.; Llompart, A.; Cabeza, E.; Germà, J.R.; Obrador, A.; Capellá, G. Founder Mutation in Familial Adenomatous Polyposis (FAP) in the Balearic Islands. Cancer Genet. Cytogenet. 2005, 158, 70–74. [Google Scholar] [CrossRef]
  50. Rivera, B.; González, S.; Sánchez-Tomé, E.; Blanco, I.; Mercadillo, F.; Letón, R.; Benítez, J.; Robledo, M.; Capellá, G.; Urioste, M. Clinical and Genetic Characterization of Classical Forms of Familial Adenomatous Polyposis: A Spanish Population Study. Ann. Oncol. 2011, 22, 903–909. [Google Scholar] [CrossRef] [PubMed]
  51. Spirio, L.; Green, J.; Robertson, J.; Robertson, M.; Otterud, B.; Sheldon, J.; Howse, E.; Green, R.; Groden, J.; White, R.; et al. The Identical 5’ Splice-Site Acceptor Mutation in Five Attenuated APC Families from Newfoundland Demonstrates a Founder Effect. Hum. Genet. 1999, 105, 388–398. [Google Scholar] [CrossRef]
  52. Moisio, A.-L.; Järvinen, H.; Peltomäki, P. Genetic and Clinical Characterisation of Familial Adenomatous Polyposis: A Population Based Study. Gut 2002, 50, 845–850. [Google Scholar] [CrossRef] [Green Version]
  53. Stekrova, J.; Sulova, M.; Kebrdlova, V.; Zidkova, K.; Kotlas, J.; Ilencikova, D.; Vesela, K.; Kohoutova, M. Novel APC Mutations in Czech and Slovak FAP Families: Clinical and Genetic Aspects. BMC Med. Genet. 2007, 8, 16. [Google Scholar] [CrossRef] [Green Version]
  54. Schwarzová, L.; Štekrová, J.; Florianová, M.; Novotný, A.; Schneiderová, M.; Lněnička, P.; Kebrdlová, V.; Kotlas, J.; Veselá, K.; Kohoutová, M. Novel Mutations of the APC Gene and Genetic Consequences of Splicing Mutations in the Czech FAP Families. Fam. Cancer 2013, 12, 35–42. [Google Scholar] [CrossRef]
  55. Wang, D.; Zhang, Z.; Li, Y.; Xu, C.; Yu, Y.; Li, M.; Chen, C.; Zhang, X. Adenomatous Polyposis Coli Gene Mutations in 22 Chinese Pedigrees with Familial Adenomatous Polyposis. Med. Sci. Monit. 2019, 25, 3796–3803. [Google Scholar] [CrossRef] [PubMed]
  56. Armstrong, J.G.; Davies, D.R.; Guy, S.P.; Frayling, I.M.; Evans, D.G. APC Mutations in Familial Adenomatous Polyposis Families in the Northwest of England. Hum. Mutat. 1997, 10, 376–380. [Google Scholar] [CrossRef]
  57. Yurgelun, M.B.; Kulke, M.H.; Fuchs, C.S.; Allen, B.A.; Uno, H.; Hornick, J.L.; Ukaegbu, C.I.; Brais, L.K.; McNamara, P.G.; Mayer, R.J.; et al. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J. Clin. Oncol. 2017, 35, 1086–1095. [Google Scholar] [CrossRef]
  58. Susswein, L.R.; Marshall, M.L.; Nusbaum, R.; Vogel Postula, K.J.; Weissman, S.M.; Yackowski, L.; Vaccari, E.M.; Bissonnette, J.; Booker, J.K.; Cremona, M.L.; et al. Pathogenic and Likely Pathogenic Variant Prevalence among the First 10,000 Patients Referred for next-Generation Cancer Panel Testing. Genet. Med. 2016, 18, 823–832. [Google Scholar] [CrossRef] [Green Version]
  59. Kaufmann, A.; Vogt, S.; Uhlhaas, S.; Stienen, D.; Kurth, I.; Hameister, H.; Mangold, E.; Kötting, J.; Kaminsky, E.; Propping, P.; et al. Analysis of Rare APC Variants at the MRNA Level: Six Pathogenic Mutations and Literature Review. J. Mol. Diagn. 2009, 11, 131–139. [Google Scholar] [CrossRef] [Green Version]
  60. Spier, I.; Horpaopan, S.; Vogt, S.; Uhlhaas, S.; Morak, M.; Stienen, D.; Draaken, M.; Ludwig, M.; Holinski-Feder, E.; Nöthen, M.M.; et al. Deep Intronic APC Mutations Explain a Substantial Proportion of Patients with Familial or Early-Onset Adenomatous Polyposis. Hum. Mutat. 2012, 33, 1045–1050. [Google Scholar] [CrossRef] [PubMed]
  61. van der Klift, H.M.; Jansen, A.M.L.; van der Steenstraten, N.; Bik, E.C.; Tops, C.M.J.; Devilee, P.; Wijnen, J.T. Splicing Analysis for Exonic and Intronic Mismatch Repair Gene Variants Associated with Lynch Syndrome Confirms High Concordance between Minigene Assays and Patient RNA Analyses. Mol. Genet. Genom. Med. 2015, 3, 327–345. [Google Scholar] [CrossRef] [PubMed]
  62. Won, Y.J.; Park, K.J.; Kwon, H.J.; Lee, J.H.; Kim, J.H.; Kim, Y.J.; Chun, S.H.; Han, H.J.; Park, J.G. Germline Mutations of the APC Gene in Korean Familial Adenomatous Polyposis Patients. J. Hum. Genet. 1999, 44, 103–108. [Google Scholar] [CrossRef] [Green Version]
  63. Sheng, J.-Q.; Cui, W.-J.; Fu, L.; Jin, P.; Han, Y.; Li, S.-J.; Fan, R.-Y.; Li, A.-Q.; Zhang, M.-Z.; Li, S.-R. APC Gene Mutations in Chinese Familial Adenomatous Polyposis Patients. World J. Gastroenterol. 2010, 16, 1522–1526. [Google Scholar] [CrossRef]
  64. Wallis, Y.L.; Morton, D.G.; McKeown, C.M.; Macdonald, F. Molecular Analysis of the APC Gene in 205 Families: Extended Genotype-Phenotype Correlations in FAP and Evidence for the Role of APC Amino Acid Changes in Colorectal Cancer Predisposition. J. Med. Genet. 1999, 36, 14–20. [Google Scholar] [PubMed]
  65. van der Luijt, R.B.; Khan, P.M.; Vasen, H.F.; Tops, C.M.; van Leeuwen-Cornelisse, I.S.; Wijnen, J.T.; van der Klift, H.M.; Plug, R.J.; Griffioen, G.; Fodde, R. Molecular Analysis of the APC Gene in 105 Dutch Kindreds with Familial Adenomatous Polyposis: 67 Germline Mutations Identified by DGGE, PTT, and Southern Analysis. Hum. Mutat. 1997, 9, 7–16. [Google Scholar] [CrossRef]
  66. Kim, D.-W.; Kim, I.-J.; Kang, H.C.; Park, H.-W.; Shin, Y.; Park, J.-H.; Jang, S.-G.; Yoo, B.C.; Lee, M.R.; Hong, C.W.; et al. Mutation Spectrum of the APC Gene in 83 Korean FAP Families. Hum. Mutat. 2005, 26, 281. [Google Scholar] [CrossRef]
  67. Lagarde, A.; Rouleau, E.; Ferrari, A.; Noguchi, T.; Qiu, J.; Briaux, A.; Bourdon, V.; Rémy, V.; Gaildrat, P.; Adélaïde, J.; et al. Germline APC Mutation Spectrum Derived from 863 Genomic Variations Identified through a 15-Year Medical Genetics Service to French Patients with FAP. J. Med. Genet. 2010, 47, 721–722. [Google Scholar] [CrossRef] [Green Version]
  68. Kanter-Smoler, G.; Fritzell, K.; Rohlin, A.; Engwall, Y.; Hallberg, B.; Bergman, A.; Meuller, J.; Grönberg, H.; Karlsson, P.; Björk, J.; et al. Clinical Characterization and the Mutation Spectrum in Swedish Adenomatous Polyposis Families. BMC Med. 2008, 6, 10. [Google Scholar] [CrossRef] [Green Version]
  69. Iwaizumi, M.; Tao, H.; Yamaguchi, K.; Yamada, H.; Shinmura, K.; Kahyo, T.; Yamanaka, Y.; Kurachi, K.; Sugimoto, K.; Furukawa, Y.; et al. A Novel APC Mosaicism in a Patient with Familial Adenomatous Polyposis. Hum. Genome Var. 2015, 2, 15057. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Pedemonte, S.; Sciallero, S.; Gismondi, V.; Stagnaro, P.; Biticchi, R.; Haeouaine, A.; Bonelli, L.; Nicolŏ, G.; Groden, J.; Bruzzi, P.; et al. Novel Germline APC Variants in Patients with Multiple Adenomas. Genes Chromosomes Cancer 1998, 22, 257–267. [Google Scholar] [CrossRef]
  71. Castellsagué, E.; González, S.; Guinó, E.; Stevens, K.N.; Borràs, E.; Raymond, V.M.; Lázaro, C.; Blanco, I.; Gruber, S.B.; Capellá, G. Allele-Specific Expression of APC in Adenomatous Polyposis Families. Gastroenterology 2010, 139, 439–447.e1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Fostira, F.; Thodi, G.; Sandaltzopoulos, R.; Fountzilas, G.; Yannoukakos, D. Mutational Spectrum of APC and Genotype-Phenotype Correlations in Greek FAP Patients. BMC Cancer 2010, 10, 389. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Charames, G.S.; Cheng, H.; Gilpin, C.A.; Hunter, A.G.W.; Berk, T.; Bapat, B. A Novel Aberrant Splice Site Mutation in the APC Gene. J. Med. Genet. 2002, 39, 754–757. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Gavert, N.; Yaron, Y.; Naiman, T.; Bercovich, D.; Rozen, P.; Shomrat, R.; Legum, C.; Orr-Urtreger, A. Molecular Analysis of the APC Gene in 71 Israeli Families: 17 Novel Mutations. Hum. Mutat. 2002, 19, 664. [Google Scholar] [CrossRef]
  75. Gundesen, C.; Brandt, C.A. Gene Symbol: APC. Disease: Adenomatous Polyposis Coli—Association? Hum. Genet. 2005, 117, 300. [Google Scholar]
  76. Nielsen, M.; Hes, F.J.; Nagengast, F.M.; Weiss, M.M.; Mathus-Vliegen, E.M.; Morreau, H.; Breuning, M.H.; Wijnen, J.T.; Tops, C.M.J.; Vasen, H.F.A. Germline Mutations in APC and MUTYH Are Responsible for the Majority of Families with Attenuated Familial Adenomatous Polyposis. Clin. Genet. 2007, 71, 427–433. [Google Scholar] [CrossRef]
  77. Liu, W.Q.; Dong, J.; Peng, Y.X.; Li, W.L.; Yang, J. Synonymous Mutation Adenomatous Polyposis ColiΔ486s Affects Exon Splicing and May Predispose Patients to Adenomatous Polyposis Coli/MutY DNA Glycosylase Mutation-negative Familial Adenomatous Polyposis. Mol. Med. Rep. 2018, 18, 4931–4939. [Google Scholar] [CrossRef] [Green Version]
  78. Mongin, C.; Coulet, F.; Lefevre, J.H.; Colas, C.; Svrcek, M.; Eyries, M.; Lahely, Y.; Fléjou, J.-F.; Soubrier, F.; Parc, Y. Unexplained Polyposis: A Challenge for Geneticists, Pathologists and Gastroenterologists. Clin. Genet. 2012, 81, 38–46. [Google Scholar] [CrossRef] [PubMed]
  79. Kohoutová, M.; Stekrová, J.; Jirásek, V.; Kapras, J. APC Germline Mutations Identified in Czech Patients with Familial Adenomatous Polyposis. Hum. Mutat. 2002, 19, 460–461. [Google Scholar] [CrossRef] [PubMed]
  80. Wang, D.; Liang, S.; Zhang, Z.; Zhao, G.; Hu, Y.; Liang, S.; Zhang, X.; Banerjee, S. A Novel Pathogenic Splice Acceptor Site Germline Mutation in Intron 14 of the APC Gene in a Chinese Family with Familial Adenomatous Polyposis. Oncotarget 2017, 8, 21327–21335. [Google Scholar] [CrossRef] [Green Version]
  81. Cao, X.; Hong, Y.; Eu, K.W.; Loi, C.; Cheah, P.Y. Singapore Familial Adenomatous Polyposis (FAP) Patients with Classical Adenomatous Polyposis but Undetectable APC Mutations Have Accelerated Cancer Progression. Am. J. Gastroenterol. 2006, 101, 2810–2817. [Google Scholar] [CrossRef]
  82. Montera, M.; Piaggio, F.; Marchese, C.; Gismondi, V.; Stella, A.; Resta, N.; Varesco, L.; Guanti, G.; Mareni, C. A Silent Mutation in Exon 14 of the APC Gene Is Associated with Exon Skipping in a FAP Family. J. Med. Genet. 2001, 38, 863–867. [Google Scholar] [CrossRef] [Green Version]
  83. Rohlin, A.; Rambech, E.; Kvist, A.; Törngren, T.; Eiengård, F.; Lundstam, U.; Zagoras, T.; Gebre-Medhin, S.; Borg, Å.; Björk, J.; et al. Expanding the Genotype-Phenotype Spectrum in Hereditary Colorectal Cancer by Gene Panel Testing. Fam. Cancer 2017, 16, 195–203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Gonçalves, V.; Theisen, P.; Antunes, O.; Medeira, A.; Ramos, J.S.; Jordan, P.; Isidro, G. A Missense Mutation in the APC Tumor Suppressor Gene Disrupts an ASF/SF2 Splicing Enhancer Motif and Causes Pathogenic Skipping of Exon 14. Mutat. Res. 2009, 662, 33–36. [Google Scholar] [CrossRef] [PubMed]
  85. Mucaki, E.J.; Shirley, B.C.; Rogan, P.K. Prediction of Mutant MRNA Splice Isoforms by Information Theory-Based Exon Definition. Hum. Mutat. 2013, 34, 557–565. [Google Scholar] [CrossRef]
  86. Tao, H.; Shinmura, K.; Yamada, H.; Maekawa, M.; Osawa, S.; Takayanagi, Y.; Okamoto, K.; Terai, T.; Mori, H.; Nakamura, T.; et al. Identification of 5 Novel Germline APC Mutations and Characterization of Clinical Phenotypes in Japanese Patients with Classical and Attenuated Familial Adenomatous Polyposis. BMC Res. Notes 2010, 3, 305. [Google Scholar] [CrossRef]
  87. Taki, K.; Sato, Y.; Sato, Y.; Ashihara, Y.; Chino, A.; Igarashi, M.; Sato, K.; Kitagawa, T.; Maetani, I.; Nemoto, C.; et al. A Case of a Child with an APC Pathogenic Mutation, Aberrant Expression of Splice Variants and Positive Family History of FAP. JPN J. Clin. Oncol. 2014, 44, 602–606. [Google Scholar] [CrossRef] [Green Version]
  88. Nilbert, M.; Kristoffersson, U.; Ericsson, M.; Johannsson, O.; Rambech, E.; Mangell, P. Broad Phenotypic Spectrum in Familial Adenomatous Polyposis; from Early Onset and Severe Phenotypes to Late Onset of Attenuated Polyposis with the First Manifestation at Age 72. BMC Med. Genet. 2008, 9, 101. [Google Scholar] [CrossRef] [Green Version]
  89. Chiang, J.M.; Chen, H.W.; Tang, R.P.; Chen, J.S.; Changchien, C.R.; Hsieh, P.S.; Wang, J.Y. Mutation Analysis of the APC Gene in Taiwanese FAP Families: Low Incidence of APC Germline Mutation in a Distinct Subgroup of FAP Families. Fam. Cancer 2010, 9, 117–124. [Google Scholar] [CrossRef] [PubMed]
  90. Daneberga, Z.; Berzina, D.; Borosenko, V.; Krumina, Z.; Kokaine-Sapovalova, L.; Gardovskis, A.; Berga-Svitina, E.; Gardovskis, J.; Miklasevics, E. Pathogenic APC Variants in Latvian Familial Adenomatous Polyposis Patients. Medicina (Kaunas) 2019, 55, 612. [Google Scholar] [CrossRef] [Green Version]
  91. Truta, B.; Allen, B.A.; Conrad, P.G.; Weinberg, V.; Miller, G.A.; Pomponio, R.; Lipton, L.R.; Guerra, G.; Tomlinson, I.P.M.; Sleisenger, M.H.; et al. A Comparison of the Phenotype and Genotype in Adenomatous Polyposis Patients with and without a Family History. Fam. Cancer 2005, 4, 127–133. [Google Scholar] [CrossRef]
  92. Kim, B.; Won, D.; Jang, M.; Kim, H.; Choi, J.R.; Kim, T.I.; Lee, S.-T. Next-Generation Sequencing with Comprehensive Bioinformatics Analysis Facilitates Somatic Mosaic APC Gene Mutation Detection in Patients with Familial Adenomatous Polyposis. BMC Med. Genom. 2019, 12, 103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Vietri, M.T.; Teresa, V.M.; Selvaggi, F.; Francesco, S.; De Paola, M.L.; Laura, D.P.M.; Sciaudone, G.; Guido, S.; Guadagni, I.; Ilaria, G.; et al. A Novel Frameshift Mutation in Exon 12 of the Adenomatous Polyposis Coli Gene in an Italian Family with Familial Adenomatous Polyposis and Desmoid Tumour. J. Mol. Genet. Med. 2010, 4, 235–238. [Google Scholar] [PubMed]
  94. Nilbert, M.; Fernebro, J.; Kristoffersson, U. Novel Germline APC Mutations in Swedish Patients with Familial Adenomatous Polyposis and Gardner Syndrome. Scand. J. Gastroenterol. 2000, 35, 1200–1203. [Google Scholar]
  95. Chubb, D.; Broderick, P.; Frampton, M.; Kinnersley, B.; Sherborne, A.; Penegar, S.; Lloyd, A.; Ma, Y.P.; Dobbins, S.E.; Houlston, R.S. Genetic Diagnosis of High-Penetrance Susceptibility for Colorectal Cancer (CRC) Is Achievable for a High Proportion of Familial CRC by Exome Sequencing. J. Clin. Oncol 2015, 33, 426–432. [Google Scholar] [CrossRef]
  96. Vandrovcová, J.; Stekrová, J.; Kebrdlová, V.; Kohoutová, M. Molecular Analysis of the APC and MYH Genes in Czech Families Affected by FAP or Multiple Adenomas: 13 Novel Mutations. Hum. Mutat. 2004, 23, 397. [Google Scholar] [CrossRef]
  97. Marabelli, M.; Molinaro, V.; Abou Khouzam, R.; Berrino, E.; Panero, M.; Balsamo, A.; Venesio, T.; Ranzani, G.N. Colorectal Adenomatous Polyposis: Heterogeneity of Susceptibility Gene Mutations and Phenotypes in a Cohort of Italian Patients. Genet. Test. Mol. Biomark. 2016, 20, 777–785. [Google Scholar] [CrossRef] [PubMed]
  98. Bougatef, K.; Marrakchi, R.; Moussa, A.; Blondeau-Lahely, Y.; Najjar, T.; Coulet, F.; Colas, C.; Ben Ayed, F.; Ben Ammar Elgaaied, A.; Soubrier, F. First Genetic Analysis in Tunisian Familial Adenomatous Polyposis Probands. Oncol. Rep. 2008, 19, 1213–1218. [Google Scholar] [CrossRef]
  99. Filipe, B.; Baltazar, C.; Albuquerque, C.; Fragoso, S.; Lage, P.; Vitoriano, I.; Mão de Ferro, S.; Claro, I.; Rodrigues, P.; Fidalgo, P.; et al. APC or MUTYH Mutations Account for the Majority of Clinically Well-Characterized Families with FAP and AFAP Phenotype and Patients with More than 30 Adenomas. Clin. Genet. 2009, 76, 242–255. [Google Scholar] [CrossRef] [PubMed]
  100. Zhan, Q.; Wang, L.; Xu, X.; Sun, Y.; Li, L.; Qi, X.; Chen, F.; Wei, X.; Raff, M.L.; Yu, P.; et al. An APC Mutation in a Large Chinese Kindred With Familial Adenomatous Polyposis Was Identified Using Both Next Generation Sequencing and Simple STR Marker Haplotypes. Front. Genet. 2020, 11, 191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  101. Marafie, M.; Al-Elwani, F.L.; Suliman, I.S.A. Familial Adenomatous Polyposis: Two Different APC Gene Mutations in Two Unrelated Arab Families with Differing Response to Genetic Counselling. Middle East. J. Med Genet. 2014, 3, 31–36. [Google Scholar] [CrossRef]
  102. Mutoh, M.; Akasu, T.; Takahashi, M.; Niho, N.; Yoshida, T.; Sugimura, T.; Wakabayashi, K. Possible Involvement of Hyperlipidemia in Increasing Risk of Colorectal Tumor Development in Human Familial Adenomatous Polyposis. JPN J. Clin. Oncol. 2006, 36, 166–171. [Google Scholar] [CrossRef] [Green Version]
  103. Han, S.-H.; Ryu, J.-S.; Kim, Y.-J.; Cho, H.-I.; Yang, Y.-H.; Lee, K.-R. Mutation Analysis of the APC Gene in Unrelated Korean Patients with FAP: Four Novel Mutations with Unusual Phenotype. Fam. Cancer 2011, 10, 21–26. [Google Scholar] [CrossRef]
  104. de Oliveira, J.C.; Viana, D.V.; Zanardo, C.; Santos, E.M.M.; de Paula, A.E.; Palmero, E.I.; Rossi, B.M. Genotype-Phenotype Correlation in 99 Familial Adenomatous Polyposis Patients: A Prospective Prevention Protocol. Cancer Med. 2019, 8, 2114–2122. [Google Scholar] [CrossRef] [PubMed]
  105. Ruiz-Ponte, C.; Vega, A.; Carracedo, A.; Barros, F. Mutation Analysis of the Adenomatous Polyposis Coli (APC) Gene in Northwest Spanish Patients with Familial Adenomatous Polyposis (FAP) and Sporadic Colorectal Cancer. Hum. Mutat. 2001, 18, 355. [Google Scholar] [CrossRef] [PubMed]
  106. Nilsen, T.W.; Graveley, B.R. Expansion of the Eukaryotic Proteome by Alternative Splicing. Nature 2010, 463, 457–463. [Google Scholar] [CrossRef] [Green Version]
  107. Climente-González, H.; Porta-Pardo, E.; Godzik, A.; Eyras, E. The Functional Impact of Alternative Splicing in Cancer. Cell Rep. 2017, 20, 2215–2226. [Google Scholar] [CrossRef] [Green Version]
  108. Zhang, L.; Shay, J.W. Multiple Roles of APC and Its Therapeutic Implications in Colorectal Cancer. J. Natl. Cancer Inst. 2017, 109, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  109. Su, L.K.; Barnes, C.J.; Yao, W.; Qi, Y.; Lynch, P.M.; Steinbach, G. Inactivation of Germline Mutant APC Alleles by Attenuated Somatic Mutations: A Molecular Genetic Mechanism for Attenuated Familial Adenomatous Polyposis. Am. J. Hum. Genet. 2000, 67, 582–590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Parmeggiani, F.; Pellarin, R.; Larsen, A.P.; Varadamsetty, G.; Stumpp, M.T.; Zerbe, O.; Caflisch, A.; Plückthun, A. Designed Armadillo Repeat Proteins as General Peptide-Binding Scaffolds: Consensus Design and Computational Optimization of the Hydrophobic Core. J. Mol. Biol. 2008, 376, 1282–1304. [Google Scholar] [CrossRef] [Green Version]
  111. Morishita, E.C.; Murayama, K.; Kato-Murayama, M.; Ishizuka-Katsura, Y.; Tomabechi, Y.; Hayashi, T.; Terada, T.; Handa, N.; Shirouzu, M.; Akiyama, T.; et al. Crystal Structures of the Armadillo Repeat Domain of Adenomatous Polyposis Coli and Its Complex with the Tyrosine-Rich Domain of Sam68. Structure 2011, 19, 1496–1508. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Kawasaki, Y.; Senda, T.; Ishidate, T.; Koyama, R.; Morishita, T.; Iwayama, Y.; Higuchi, O.; Akiyama, T. Asef, a Link between the Tumor Suppressor APC and G-Protein Signaling. Science 2000, 289, 1194–1197. [Google Scholar] [CrossRef]
  113. Jimbo, T.; Kawasaki, Y.; Koyama, R.; Sato, R.; Takada, S.; Haraguchi, K.; Akiyama, T. Identification of a Link between the Tumour Suppressor APC and the Kinesin Superfamily. Nat. Cell Biol. 2002, 4, 323–327. [Google Scholar] [CrossRef] [PubMed]
  114. Watanabe, T.; Wang, S.; Noritake, J.; Sato, K.; Fukata, M.; Takefuji, M.; Nakagawa, M.; Izumi, N.; Akiyama, T.; Kaibuchi, K. Interaction with IQGAP1 Links APC to Rac1, Cdc42, and Actin Filaments during Cell Polarization and Migration. Dev. Cell 2004, 7, 871–883. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Zhang, Z.; Akyildiz, S.; Xiao, Y.; Gai, Z.; An, Y.; Behrens, J.; Wu, G. Structures of the APC-ARM Domain in Complexes with Discrete Amer1/WTX Fragments Reveal That It Uses a Consensus Mode to Recognize Its Binding Partners. Cell Discov. 2015, 1, 15016. [Google Scholar] [CrossRef]
  116. Crist, R.C.; Roth, J.J.; Baran, A.A.; McEntee, B.J.; Siracusa, L.D.; Buchberg, A.M. The Armadillo Repeat Domain of Apc Suppresses Intestinal Tumorigenesis. Mamm. Genome 2010, 21, 450–457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Kawasaki, Y.; Sato, R.; Akiyama, T. Mutated APC and Asef Are Involved in the Migration of Colorectal Tumour Cells. Nat. Cell Biol. 2003, 5, 211–215. [Google Scholar] [CrossRef]
  118. Zhang, Z.; Chen, L.; Gao, L.; Lin, K.; Zhu, L.; Lu, Y.; Shi, X.; Gao, Y.; Zhou, J.; Xu, P.; et al. Structural Basis for the Recognition of Asef by Adenomatous Polyposis Coli. Cell Res. 2012, 22, 372–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  119. Tanneberger, K.; Pfister, A.S.; Kriz, V.; Bryja, V.; Schambony, A.; Behrens, J. Structural and Functional Characterization of the Wnt Inhibitor APC Membrane Recruitment 1 (Amer1). J. Biol. Chem. 2011, 286, 19204–19214. [Google Scholar] [CrossRef] [Green Version]
  120. Li, X.; Zhou, X.; Hua, F.; Fan, Y.; Zu, L.; Wang, Y.; Shen, W.; Pan, H.; Zhou, Q. The RNA-Binding Protein Sam68 Is Critical for Non-Small Cell Lung Cancer Cell Proliferation by Regulating Wnt/β-Catenin Pathway. Int. J. Clin. Exp. Pathol. 2017, 10, 8281–8291. [Google Scholar] [PubMed]
  121. Albanaz, A.T.S.; Rodrigues, C.H.M.; Pires, D.E.V.; Ascher, D.B. Combating Mutations in Genetic Disease and Drug Resistance: Understanding Molecular Mechanisms to Guide Drug Design. Expert Opin. Drug Discov. 2017, 12, 553–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  122. Trezza, A.; Bernini, A.; Langella, A.; Ascher, D.B.; Pires, D.E.V.; Sodi, A.; Passerini, I.; Pelo, E.; Rizzo, S.; Niccolai, N.; et al. A Computational Approach From Gene to Structure Analysis of the Human ABCA4 Transporter Involved in Genetic Retinal Diseases. Investig. Ophthalmol. Vis. Sci. 2017, 58, 5320–5328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Menéndez, M.; González, S.; Obrador-Hevia, A.; Domínguez, A.; Pujol, M.J.; Valls, J.; Canela, N.; Blanco, I.; Torres, A.; Pineda-Lucena, A.; et al. Functional Characterization of the Novel APC N1026S Variant Associated with Attenuated Familial Adenomatous Polyposis. Gastroenterology 2008, 134, 56–64. [Google Scholar] [CrossRef] [PubMed]
Genes 12 00353 g001 550
Figure 1. Pedigree of the Italian family involved in this study. Squares indicate men, circles represent women. The arrow indicates the index case. Unfilled symbols indicate unaffected individuals. Slashed symbols denote dead individuals. Black-filled symbols denote individuals with colorectal cancer and polyposis, while gray-filled symbols correspond to patients with colorectal polyposis. The following information is given below each filled symbol: clinical manifestations (CRC = colorectal cancer; CPs = colon polyps, with the number of polyps indicated in square brackets; Pca = prostate cancer), age at diagnosis (y = years).
Figure 1. Pedigree of the Italian family involved in this study. Squares indicate men, circles represent women. The arrow indicates the index case. Unfilled symbols indicate unaffected individuals. Slashed symbols denote dead individuals. Black-filled symbols denote individuals with colorectal cancer and polyposis, while gray-filled symbols correspond to patients with colorectal polyposis. The following information is given below each filled symbol: clinical manifestations (CRC = colorectal cancer; CPs = colon polyps, with the number of polyps indicated in square brackets; Pca = prostate cancer), age at diagnosis (y = years).
Genes 12 00353 g001
Genes 12 00353 g002 550
Figure 2. Characterization of APC splicing mutation c.1626_1627+7del. (A) Sequencing electropherograms of genomic DNA from a healthy control individual and the proband, showing the splicing mutation c.1626_1627+7del. (B) Left: Agarose gel electrophoresis showing the RT-PCR analysis of mRNA extracted from peripheral blood of the patient (P) carrying the APC c.1621_1626+7del mutation and a healthy control (C). Amplified products obtained with primers spanning APC exon 10–11 and 13–14 boundaries were separated on 3% agarose gel and independently sequenced. Center: Schematic diagrams showing the wild type amplification product (356 bp) and the altered-splicing amplification product lacking APC exon 12 (277 bp). Right: Sequencing electropherograms of cDNA splicing isoforms generated from the wild type and mutant RT-PCR products. Bottom: Diagram showing the localization of the primers (indicated as arrows) used for RT-PCR experiments.
Figure 2. Characterization of APC splicing mutation c.1626_1627+7del. (A) Sequencing electropherograms of genomic DNA from a healthy control individual and the proband, showing the splicing mutation c.1626_1627+7del. (B) Left: Agarose gel electrophoresis showing the RT-PCR analysis of mRNA extracted from peripheral blood of the patient (P) carrying the APC c.1621_1626+7del mutation and a healthy control (C). Amplified products obtained with primers spanning APC exon 10–11 and 13–14 boundaries were separated on 3% agarose gel and independently sequenced. Center: Schematic diagrams showing the wild type amplification product (356 bp) and the altered-splicing amplification product lacking APC exon 12 (277 bp). Right: Sequencing electropherograms of cDNA splicing isoforms generated from the wild type and mutant RT-PCR products. Bottom: Diagram showing the localization of the primers (indicated as arrows) used for RT-PCR experiments.
Genes 12 00353 g002
Genes 12 00353 g003 550
Figure 3. Splicing minigene reporter assay based on the pSPL3 exon-trapping vector. (A) Schematic representation of the pSPL3 minigene reporter used for the molecular characterization of APC splicing mutation c.1621_1626+7del. The pSPL3 vector contains two exons (SD and SA) and a functional intron, with transcription beginning after the SV40 promoter and ending at the late poly(A) signal (LPAS). EcoRI and BamHI indicate the cloning sites used to subclone the genomic APC fragments obtained from the wild type and mutant alleles (c.1621_1626+7del). (B) RT-PCR analysis of transcripts derived from the indicated pSPL3 reporter minigenes transfected in HEK-293 cells. Left: Agarose gel electrophoresis showing the RT-PCR products obtained with the SD6 and SA2 primers from HEK-293 cells transfected with the pSPL3 empty vector (263 bp), the pSPL3 vector with the genomic APC fragment from the wild type allele (341 bp), or the pSPL3 vector with the genomic APC fragment from the mutant allele (263 bp), and untransfected HEK-293 cells (negative control). Center: Schematic diagrams showing the RT-PCR products obtained. Right: Sequencing electropherograms of the RT-PCR products obtained.
Figure 3. Splicing minigene reporter assay based on the pSPL3 exon-trapping vector. (A) Schematic representation of the pSPL3 minigene reporter used for the molecular characterization of APC splicing mutation c.1621_1626+7del. The pSPL3 vector contains two exons (SD and SA) and a functional intron, with transcription beginning after the SV40 promoter and ending at the late poly(A) signal (LPAS). EcoRI and BamHI indicate the cloning sites used to subclone the genomic APC fragments obtained from the wild type and mutant alleles (c.1621_1626+7del). (B) RT-PCR analysis of transcripts derived from the indicated pSPL3 reporter minigenes transfected in HEK-293 cells. Left: Agarose gel electrophoresis showing the RT-PCR products obtained with the SD6 and SA2 primers from HEK-293 cells transfected with the pSPL3 empty vector (263 bp), the pSPL3 vector with the genomic APC fragment from the wild type allele (341 bp), or the pSPL3 vector with the genomic APC fragment from the mutant allele (263 bp), and untransfected HEK-293 cells (negative control). Center: Schematic diagrams showing the RT-PCR products obtained. Right: Sequencing electropherograms of the RT-PCR products obtained.
Genes 12 00353 g003
Genes 12 00353 g004 550
Figure 4. APC coding region. (A) Schematic diagram of wild type APC protein, depicting conserved regions and domains that interact with other proteins. (B) Schematic diagram of APC truncated proteins that result from total removal of ARM2 and/or ARM3 along with disruption of all downstream APC domains and are associated with the classic FAP phenotype. (C) Schematic diagram of APC variants that result from exon 12 or exon 13 splicing mutations leading to an in-frame protein and are associated with the AFAP phenotype.
Figure 4. APC coding region. (A) Schematic diagram of wild type APC protein, depicting conserved regions and domains that interact with other proteins. (B) Schematic diagram of APC truncated proteins that result from total removal of ARM2 and/or ARM3 along with disruption of all downstream APC domains and are associated with the classic FAP phenotype. (C) Schematic diagram of APC variants that result from exon 12 or exon 13 splicing mutations leading to an in-frame protein and are associated with the AFAP phenotype.
Genes 12 00353 g004
Table
Table 1. APC splicing mutations leading to an in-frame protein and skipping of exon 12 or exon 13.
Table 1. APC splicing mutations leading to an in-frame protein and skipping of exon 12 or exon 13.
GeneVariant (Human Genome Variation Society, HGVS)Chromosome
Position (GRCh37)		LocationObserved
Effect on
splicing		Effect on mRNA
(HGVS)		Effect on
Protein
(HGVS)		Clinical
Phenotype (Classic FAP/AFAP)		Reference
APCc.1621_1626+7delchr5:g.112163698-
112163710del		Exon 12/
Intron 12		Exon 12
skipping		r.1549_1626delp.A517_Q542delAFAPPresent study
APCc.1626G>Cchr5:g.112164552G>CExon 12Exon 12
skipping		r.1549_1626delp.A517_Q542deln.d.[45]
APCc.1627G>Tchr5:g.112164553G>TExon 13Exon 13
skipping		r.1627_1743delp.V543_K581delAFAP[54]
APCc.1742A>Gchr5:g.112164668A>GExon 13Exon 13
skipping		r.1627_1743delp.V543_K581delAFAP[59]
n.d.: not discriminated.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Disciglio, V.; Forte, G.; Fasano, C.; Sanese, P.; Lepore Signorile, M.; De Marco, K.; Grossi, V.; Cariola, F.; Simone, C. APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome. Genes 2021, 12, 353. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12030353

AMA Style

Disciglio V, Forte G, Fasano C, Sanese P, Lepore Signorile M, De Marco K, Grossi V, Cariola F, Simone C. APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome. Genes. 2021; 12(3):353. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12030353

Chicago/Turabian Style

Disciglio, Vittoria, Giovanna Forte, Candida Fasano, Paola Sanese, Martina Lepore Signorile, Katia De Marco, Valentina Grossi, Filomena Cariola, and Cristiano Simone. 2021. "APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome" Genes 12, no. 3: 353. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12030353

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop